Bipolar I Disorder Clinical Trials

17 recruiting

Bipolar I Disorder Trials at a Glance

17 actively recruiting trials for bipolar i disorder are listed on ClinicalTrialsFinder across 6 cities in 12 countries. The largest study group is Phase 2 with 8 trials, with the heaviest enrollment activity in Atlanta, Everett, and Decatur. Lead sponsors running bipolar i disorder studies include AbbVie, Mclean Hospital, and Alzamend Neuro, Inc..

Browse bipolar i disorder trials by phase

Treatments under study

About Bipolar I Disorder Clinical Trials

Looking for clinical trials for Bipolar I Disorder? There are currently 17 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Bipolar I Disorder trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Bipolar I Disorder clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 117 of 17 trials

Recruiting
Not Applicable

SYNCED - SYNChronized Eating in Bipolar Depression Study

Bipolar I DisorderBipolar II DisorderBipolar Depression
University of Ottawa40 enrolled1 locationNCT06560957
Recruiting
Phase 1Phase 2

Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine

SchizophreniaMajor Depressive DisorderBipolar I Disorder
Mapi Pharma Ltd.24 enrolled6 locationsNCT07185815
Recruiting
Phase 1Phase 2

A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder

Bipolar I Disorder
Alzamend Neuro, Inc.20 enrolled1 locationNCT07540338
Recruiting
Phase 2

Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

Bipolar I Disorder
LB Pharmaceuticals Inc.320 enrolled3 locationsNCT07494305
Recruiting
Phase 2

A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder

Bipolar I DisorderBipolar II Disorder
AbbVie195 enrolled29 locationsNCT06696755
Recruiting
Phase 3

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

Bipolar DisorderBipolar I DisorderBipolar II Disorder+1 more
Xenon Pharmaceuticals Inc.400 enrolled27 locationsNCT07172516
Recruiting
Phase 3

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

DepressionBipolar I Disorder
AbbVie380 enrolled80 locationsNCT04777357
Recruiting
Phase 2

An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania

Bipolar I DisorderMania
Neurocrine Biosciences150 enrolled6 locationsNCT07288320
Recruiting

LHC-CIDI-5 in Hong Kong

Suicidal IdeationMajor Depressive Disorder (MDD)Bipolar I Disorder+14 more
The University of Hong Kong2,500 enrolled1 locationNCT06804525
Recruiting
Phase 4

Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

ObesityWeight LossBipolar I Disorder+3 more
Mayo Clinic100 enrolled1 locationNCT07213466
Recruiting
Phase 3

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

SchizophreniaBipolar I Disorder
Alkermes, Inc.220 enrolled47 locationsNCT05303064
Recruiting

Children's Bipolar Network Treatment Trial I

Bipolar DisorderBipolar I DisorderBipolar II Disorder+1 more
University of California, Los Angeles80 enrolled4 locationsNCT05427123
Recruiting
Phase 2

Efficacy and Safety of Magnesium Vitamin B6 in First Episode Bipolar Disorder

Depression, AnxietyStressBipolar I Disorder
Mclean Hospital40 enrolled1 locationNCT05837104
Recruiting
Not Applicable

Ketogenic and Nutritional Interventions for First Episode Bipolar Disorder

Bipolar I DisorderPsychosisSchizoaffective Disorder
Mclean Hospital50 enrolled1 locationNCT06221852
Recruiting
Phase 2

Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders

Cannabis UseBipolar DisorderSchizoaffective Disorder, Bipolar Type+5 more
Medical University of South Carolina68 enrolled1 locationNCT05064319
Recruiting
Phase 4

Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

SchizophreniaBipolar I Disorder
Vanda Pharmaceuticals100 enrolled9 locationsNCT05648591
Recruiting
Phase 2

NMDA Receptor Modulation for the Treatment of Bipolar I Disorder

Bipolar I Disorder
China Medical University Hospital90 enrolled1 locationNCT05977023